Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer

In advanced lung cancer, epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) have extraordinary clinical efficacy. However, their usefulness is severely compromised by drug resistance mediated by various mechanisms, the most important of which is the secondary EGFR T790M mutation. The mut...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Autores principales: Li, Hongjian, Tong, Christy Wing-Sum, Leung, Yee, Wong, Man-Hon, To, Kenneth Kin-Wah, Leung, Kwong-Sak
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2017
Materias:
Oncology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5712561/
https://ncbi.nlm.nih.gov/pubmed/29238696
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2017.00288
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares